Kelly Huang, Elucid - Studio Interview | LSI USA '25

 Elucid is a Boston-based medical technology company using histology-validated software to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid’s CTA analysis equips physicians with critical information designed to enable precision medicine. For more information watch this video: https://www.lifesciencemarketresearch.com/videos/kelly-huang-elucid-studio-interview-lsi-usa-25

Comments

Post a Comment

Popular posts from this blog

Big Tech and Big Pharma: How Medtech Can Bridge the Gap

As technologies evolve and  healthcare innovation  accelerates, the traditional boundaries separating medtech, big tech, and big pharma are increasingly blurry — but the cultural and strategic gaps between them remain. At LSI USA ’25, panelists Juan-Pablo Mas (Action Potential Venture Capital), Nishant Doctor (Surf Therapeutics), and Jordi Parramon (Nexus NeuroTech Ventures) joined moderator Katie Elias to examine how medtech can better align with  big tech and big pharma  to drive innovation forward. The conversation centered on key differences in development strategy, investor expectations, and business timelines — critical challenges that arise when building partnerships or raising capital across sectors. As medtech companies seek broader platforms and more ambitious outcomes, understanding and navigating these differences becomes essential for effective cross-sector collaboration and long-term success. Understanding the Evidence Gap A major area of divergence bet...
Read more